Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 16,806 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Symptom Clusters Clear all
Completed Not applicable Interventional

The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

NCT00002387
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Efavirenz
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Not applicable Interventional

Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device

NCT02102087
View directory record Official record
Conditions
Septicemia
Interventions
Initial Specimen Diversion Device (ISDD), Lab standard practice (LSP)
Device
Lead sponsor
Magnolia Medical Technologies, Inc.
Industry
Eligibility
19 Years and older
Enrollment
971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

NCT00003816
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Nonmalignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anti-thymocyte globulin, busulfan, carboplatin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, thiotepa, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
4 Years to 70 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 21, 2026, 1:22 AM EDT
Withdrawn Phase 2 Interventional

Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain

NCT00795106
View directory record Official record
Conditions
Myofascial Pain Syndrome
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

NCT03231306
View directory record Official record
Conditions
Neurofibromatosis Type 1, Plexiform Neurofibroma
Interventions
Binimetinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 21, 2026, 1:22 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

NCT06566742
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance
Interventions
Olutasidenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

NCT03126370
View directory record Official record
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 2 Interventional

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

NCT00001083
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
58
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 1:22 AM EDT
Completed No phase listed Observational

Diagnostic Validation of Drug-Induced Sleep Endoscopy (DISE)

NCT03391141
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Dr. Erica Thaler
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 21, 2026, 1:22 AM EDT
Completed No phase listed Observational

The Prevalence and Risk Factors of Sleep Disordered Breathing in a Heart Failure Program

NCT00679822
View directory record Official record
Conditions
Sleep Apnea, Heart Failure
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

NCT00903422
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
eltrombopag olamine, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
24
States / cities
Birmingham, Alabama • Santa Monica, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 2 Interventional Results available

Early Metabolic Resuscitation for Septic Shock

NCT03895853
View directory record Official record
Conditions
Multiple Organ Failure, Septic Shock, Severe Sepsis
Interventions
Best Practice, early metabolic resuscitation
Other · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated No phase listed Observational

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

NCT00813501
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Neuroblastoma, Therapy-related Toxicity
Interventions
immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 2 Interventional

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

NCT03845712
View directory record Official record
Conditions
Thymidine Kinase 2 Deficiency
Interventions
doxecitine and doxribtimine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Not applicable Interventional

Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease

NCT00002081
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wellesley Hills, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 4 Interventional Results available

Validation of a Real-time Urodynamic Measure of Urinary Urgency

NCT00909428
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Solifenacin Succinate
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Quantitative Genioglossal Muscle Strength in Obstructive Sleep Apnea (OSAS)

NCT02695667
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
20 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 21, 2026, 1:22 AM EDT
Recruiting No phase listed Observational

Brain Development Research Program

NCT00305305
View directory record Official record
Conditions
Brain Disorders, Aicardi Syndrome
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Recruiting No phase listed Observational

Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing

NCT06749366
View directory record Official record
Conditions
Enchondromatosis
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Recruiting Not applicable Interventional

Emovi 3D Knee Assessment Device Intervention for Operational Readiness

NCT06517056
View directory record Official record
Conditions
Patellofemoral Pain, Patellofemoral Pain Syndrome
Interventions
Emovi Knee Kinesiography
Device
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Honolulu, Hawaii • Fort Liberty, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

NCT07066722
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 21, 2026, 1:22 AM EDT